A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE 2B TRIAL TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AEF0217 FOR 24 WEEKS IN ADULTS AND OLDER ADOLESCENTS WITH DOWN SYNDROME - AEF0217-201
Latest Information Update: 11 Dec 2025
At a glance
- Drugs AEF 0217 (Primary)
- Indications Cognition disorders; Down syndrome
- Focus Therapeutic Use
- Acronyms AEF0217-201
- Sponsors Aelis Farma
Most Recent Events
- 11 Dec 2025 New trial record